Drug intelligence / Profile preview

OBN-06

Development stage: Preclinical
Lead developer: Oban BioPharma
Modality: Small Molecules
Administration: Oral

Overview

OBN-06 is an orally bioavailable small molecule developed by Oban BioPharma that acts as a positive allosteric modulator and agonist (Ago-PAM) of the muscarinic M4 receptor. By selectively targeting the M4 receptor, OBN-06 is designed to modulate dopaminergic activity in the brain, offering a potential therapeutic approach for neuropsychiatric and neurodegenerative conditions without the side effects associated with direct dopamine receptor antagonism. The compound is currently in IND-enabling studies for the treatment of schizophrenia, Alzheimer's disease psychosis, and L-DOPA-induced dyskinesia in Parkinson's disease.

Other names: Muscarinic M4 Ago-PAM

Targets

CHRM4 (M4)

Beyond the preview

Go deeper on OBN-06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OBN-06.

Explore the full profile